The world of external support to advance drug discovery has changed dramatically in the last 20 years. We are now in a position where we can truly rely on external partners to ‘get the job done’ and can run our programs almost entirely virtually from early target validation all the way through IND enabling studies, FIH, and beyond. This talk will explain some of the newer working models of support and the innovative ways service providers are finding to support their customers. In particular, it will focus on the science around select case studies in oncology and neuroscience where ChemPartner has partnered with groups to push projects efficiently to a key inflection point.
These case studies will showcase the key decision-making criteria biopharmaceutical companies use to determine their ‘partner of choice.’ Additionally, we’ll review the kinds of high-end science that pharma and biotech companies can now find outside of their own walls and how groups can come together to achieve common goals. Lastly, we’ll discuss ways to form strategic partnerships with different groups in a real ‘win-win’ scenario where all partners participate in the upsides of success. This goes beyond traditional ‘risk share’ which are more ‘risk mitigation’ strategies on the part of groups looking to parse off risk where outcomes are less certain, but more where savvy groups come together for mutual benefit and true and lasting partnerships form.
Sarah Lively, VP Innovation and New Technology, ChemPartner
Dr Sarah Lively is a synthetic organic chemist by training. She got her Bachelors Degree in Chemistry from Loughborough University and her PhD in synthetic methodology (asymmetric catalysis) in the Aggarwal group at Sheffield University, both in the United Kingdom. She started her career at GSK in their PRD group in the UK and after various moves ended up in the UK division of Tularik Inc. Amgen’s acquisition of Tularik in 2004 saw Dr. Lively’s move to California where she led small molecule therapeutic projects for Amgen. Sarah joined ChemPartner in 2014 and set up their operations in South San Francisco. Today, Dr. Lively leads a group of over 20 talented scientists, and, as part of the overall ChemPartner leadership team, is specifically responsible for innovation, new technologies, and strategic partnerships. Her experience spans a wide variety of therapeutic areas and modalities and her talented leadership has led to multiple important projects and relationships for ChemPartner.Message Presenter
Who Should Attend?
- Biotechnology Professionals, Including Chemists, Biologists, DMPK Scientists
- Academic Professionals, Including Chemistry, Biology, Biochemistry, Translational Research
- Pharmaceutical Professionals: Chemists, Biologists, DMPK Scientists, Pharmacologists
What You Will Learn
- New ways to work with external partners
- Leveraging academic research utilizing a CRO partner
- Science across multiple sites for oncology and neuroscience projects
Shanghai ChemPartner, which includes ChemPartner, ChemPartner Biologics, and China Gateway Pharmaceutical Development, offers a broad range of drug discovery, development, and manufacturing services including chemistry and biologics discovery, biology, pharmacology, DMPK, and exploratory toxicology as well as small molecule and biologics CMC development and manufacturing. Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices, and representatives in the US, Europe, China, and Japan. As more and more biopharmaceutical companies look for alliance partners to provide intellectual contributions and exceptional technical expertise, ChemPartner is uniquely positioned to not only be a CRO, but to be a true pharmaceutical alliance partner. With a team of over 2000 experienced scientists, hundreds of western-trained pharmaceutical industry leaders, and experienced pharmaceutical executive leadership at the helm, ChemPartner is aligned and dedicated to technically and strategically accomplishing the research initiatives of pharma and biotech companies worldwide.